Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.

The Affiliate Leaders Summit will take its next major step in 2026, evolving into a standalone global…

Yango Group, a UAE based tech company, has invested through its corporate venture fund, Yango Ventures, in Egypt-based Fincart as part of the e-commerce operations platform’s oversubscribed $2.8 million seed… The post Yango Group invests in Egypt’s Fincart in $2.8 million seed round appeared first on Web-Release.